The new pairing combines Tandem’s flagship automated insulin delivery system with Control-IQ+ technology with Abbott’s latest continuous glucose monitor (CGM) sensor in the U.S. Tandem teased the launch on social media earlier this month after the companies first agreed to integrate systems in June. At that point, Tandem already initiated an early access program for integration in the U.S. with plans to scale availability in the second half of 2025.
It marks the latest integration between the diabetes technology developers — two of the world’s largest — following the integration of FreeStyle Libre 2 Plus CGM into the t:slim X2 insulin pump in January 2024. Earlier this year, the companies announced the future pairing of Tandem systems with Abbott’s under-development dual glucose-ketone sensor.
Read more about Tandem, Abbott and the rest of the diabetes tech industry in our free Diabetes Technology Special Report.
Abbott’s FreeStyle Libre 3 Plus is the company’s latest-generation CGM designed for insulin pump integration. Its readings every minute can help insulin pumps adjust to users’ needs. The system also offers a 15-day wear time.
t:slim X2, powered by Control-IQ+ technology, has an advanced hybrid closed-loop automated insulin delivery feature. It predicts and helps prevent high and low blood sugar. Control-IQ leads to improved time in range throughout the day and night. Tandem unveiled the next-generation algorithm earlier this year.
Tandem said it pre-loaded updated software for the Libre 3 Plus sensor integration on all new pump shipments. All eligible t:slim X2 users can also access the software through an update. The company plans to launch international early access programs before the end of the year, then scale commercial availability in 2026.
San Diego-based Tandem plans to email all eligible pump users in the U.S. with instructions on adding the new compatibility free of charge.
“With this integration, we expand the benefits of greater control to more people living with diabetes worldwide with our AID system that is easy to start, use, and personalize,” said John Sheridan, Tandem president and CEO. “It combines Control-IQ+, our most advanced algorithm ever, together with the benefits of Abbott’s latest CGM sensor on our tested and trusted t:slim X2 insulin pump.”
